Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICER 2020 Priorities Include Drugs For Ulcerative Colitis, NASH And Gene Therapies

Executive Summary

The Institute for Clinical and Economic Review has a full agenda planned for 2020, starting with potential new oral drugs for migraine.

You may also be interested in...



Novartis CEO Explains Delay In Telling US FDA About Zolgensma Data Fraud: We Wanted To Understand It First

Novartis is in the process of "exiting" the "small number" of scientists involved in the fraud, CEO Narasimhan says.

Bluebird Pushes For Zynteglo Pricing Of Five €315K Annual Installments

CEO Nick Leschly talked to Scrip about the European payment strategy for the one-time gene therapy, which will cost €1.575m over five years if treatment is successful.

CymaBay Alters NASH Hypothesis After Phase IIb Failure In Hepatic Fat Reduction

Firm points to liver biomarker findings, saying they may yield clear liver benefit at 52 weeks. Both CymaBay's and Genfit's stock prices fell as investors wondered about broader read-through for the PPAR agonist class.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

WI964834

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel